The Senate Finance Committee faces opposition from the pharmaceutical industry after releasing a bipartisan drug-pricing proposal on Tuesday that could potentially cap seniors’ out-of-pocket costs and limit price increases in Medicare.
The Senate Finance Committee faces opposition from the pharmaceutical industry after releasing a bipartisan drug-pricing proposal on Tuesday that could potentially cap seniors’ out-of-pocket costs and limit price increases in Medicare.
